1. Home
  2. LEGN vs EXP Comparison

LEGN vs EXP Comparison

Compare LEGN & EXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • EXP
  • Stock Information
  • Founded
  • LEGN 2014
  • EXP 1963
  • Country
  • LEGN United States
  • EXP United States
  • Employees
  • LEGN N/A
  • EXP N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • EXP Building Materials
  • Sector
  • LEGN Health Care
  • EXP Industrials
  • Exchange
  • LEGN Nasdaq
  • EXP Nasdaq
  • Market Cap
  • LEGN 7.0B
  • EXP 7.6B
  • IPO Year
  • LEGN 2020
  • EXP 1994
  • Fundamental
  • Price
  • LEGN $33.65
  • EXP $218.81
  • Analyst Decision
  • LEGN Strong Buy
  • EXP Buy
  • Analyst Count
  • LEGN 13
  • EXP 11
  • Target Price
  • LEGN $79.17
  • EXP $286.36
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • EXP 404.3K
  • Earning Date
  • LEGN 03-11-2025
  • EXP 05-20-2025
  • Dividend Yield
  • LEGN N/A
  • EXP 0.45%
  • EPS Growth
  • LEGN N/A
  • EXP N/A
  • EPS
  • LEGN N/A
  • EXP 13.93
  • Revenue
  • LEGN $627,241,000.00
  • EXP $2,267,040,000.00
  • Revenue This Year
  • LEGN $66.60
  • EXP $1.76
  • Revenue Next Year
  • LEGN $49.28
  • EXP $5.39
  • P/E Ratio
  • LEGN N/A
  • EXP $15.87
  • Revenue Growth
  • LEGN 119.97
  • EXP 0.64
  • 52 Week Low
  • LEGN $30.17
  • EXP $205.44
  • 52 Week High
  • LEGN $60.87
  • EXP $321.93
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 44.07
  • EXP 39.17
  • Support Level
  • LEGN $34.00
  • EXP $212.27
  • Resistance Level
  • LEGN $36.20
  • EXP $232.08
  • Average True Range (ATR)
  • LEGN 1.52
  • EXP 6.12
  • MACD
  • LEGN -0.25
  • EXP 1.58
  • Stochastic Oscillator
  • LEGN 25.18
  • EXP 32.22

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About EXP Eagle Materials Inc

Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.

Share on Social Networks: